Purchase Order 75N95024P00169
- Not listed
- This firm-fixed-price purchase order contract was awarded by the National Institute on Drug Abuse, a civilian agency within the U.S. Department of Health and Human Services, to Insphero Inc., a foreign-owned, for-profit manufacturer of advanced 3D cell culture technologies. The $46,829.63 contract tasks Insphero with providing 3D liver microtissues composed of human primary hepatocytes and other liver cells, which are used for drug-induced liver injury assays and toxicity testing. These...
- The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, awarded a $75,000.00 firm-fixed-price purchase order to Insphero Inc., a foreign-owned for-profit manufacturer of advanced 3D cell culture products. The contract is for safety assessment studies using Insphero's human, mouse, and rat 3D liver spheroid models to evaluate drug-induced liver injury (DILI) as part of the DILIPLUS assay program. This contract...
- This is a $90,414 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services, to Insphero Inc., a foreign-owned, for-profit manufacturer of 3D cell culture technologies and in vitro models. The contract is for a Liver Assay in Liver Spheroids to evaluate the toxicity of short interfering RNA (siRNA) and antisense oligonucleotides (ASOs), which are increasingly being used as...
- This federal contract award, valued at $34,276.75, was issued by the National Institute on Drug Abuse (NIDA), a civilian agency within the Department of Health and Human Services (HHS), to Insphero Inc., a foreign-owned, for-profit manufacturer of 3D cell culture technologies and in vitro models. The contract is for the delivery of 3D liver microtissues composed of human primary hepatocytes, liver endothelial cells, and Kupffer cells, which will be used by NIDA's 3D Tissue Bioprinting Laboratory...
- This is a $24,900 firm-fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Center for Advancing Translational Sciences to 3Dnamics Inc., a biotechnology company that provides stem cell engineering technology and related services. The contract is for the differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte organoids, which are three-dimensional cell cultures that model liver tissue. This work supports...
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences awarded a Small Business Innovation Research (SBIR) Phase II contract to Mimetas US, Inc., a self-certified small disadvantaged business, to develop and evaluate the HEPAPLATE IPS, a high-throughput organ-on-a-chip in vitro hepatotoxicity screening platform. The $1,500,000.00 firm fixed price contract was awarded on February 8, 2018, with a completion date of...
- This purchase order contract was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Life Technologies Corporation for the delivery of 50 vials of human spheroid-qualified hepatocytes. As described in the original solicitation, these liver cells will support the National Institute on Drug Abuse's Antiviral Program for Pandemics by enabling the continued identification of direct-acting antivirals and development of microphysiological systems...
- The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a $150,000.00 firm fixed-price purchase order to 3Dnamics Inc., a biotechnology company, for services related to the differentiation and characterization of induced pluripotent stem cell (iPSC) lines. This non-competitive commercial item acquisition was conducted under simplified acquisition procedures without a small business set-aside. The services...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to Mimetas US Inc., a self-certified small disadvantaged business. The $224,998 Firm Fixed Price contract is for the "Development and Evaluation of the HepaPlate IPS: A High Throughput Organ on a Chip IPS Hepatotoxicity Screening Platform." The contract aims to develop and evaluate a high-throughput organ-on-a-chip...
- This $25,100 firm-fixed-price purchase order was awarded by the National Institute on Drug Abuse (NIDA) to Lifenet Health, a non-profit organization and manufacturer of regenerative medicine products, to conduct 3D liver spheroid assays for pharmacogenomics-based prediction of drug-induced liver injury (DILI). The award has a period of performance through September 29, 2025 and was not set aside for any particular business type. Lifenet Health is a specialized provider of human tissues and...
Insphero, Inc. has been awarded a firm fixed price purchase order valued at twenty-two thousand eight hundred dollars from the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences. The contract calls for Insphero to provide 3D liver microtissues composed of human primary hepatocytes and liver cells for drug testing and safety assessments. Insphero will deliver the 3D liver spheroids to support drug-induced liver injury assays under the contract, which has a period of performance through July 1, 2024 and did not utilize any set-aside designations. Insphero is a leading supplier of organotypic biological in vitro 3D microtissues for highly predictive drug testing and has received multiple federal contract awards from HHS totaling over $100,000 to support toxicity testing programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.8k | 3/5/24 |